Sinsin Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	4,373	3,876	539.85	346.46	2,240	799.33
Cash & Short-Term Investments	4,373	3,876	539.85	346.46	2,240	799.33
Cash Growth	356.19%	618.05%	55.82%	-84.53%	180.24%	-68.08%
Accounts Receivable	34,312	32,808	30,605	27,975	25,771	23,237
Other Receivables	2,190	2,061	2,229	2,216	1,953	1,652
Receivables	36,502	34,869	32,833	30,191	27,724	24,889
Inventory	21,268	19,976	16,643	15,733	14,390	10,370
Prepaid Expenses	137.2	140.27	103.01	160.45	34.91	33.79
Other Current Assets	952.96	558.51	1,374	676.95	659.08	375.07
Total Current Assets	63,234	59,420	51,492	47,108	45,048	36,467
Property, Plant & Equipment	63,399	64,020	65,718	68,264	66,825	69,345
Long-Term Investments	8,729	7,652	6,649	3,270	3,559	3,183
Other Intangible Assets	559.09	563.38	580.53	586.32	592.29	499.07
Long-Term Accounts Receivable	-0	0	-0	-0	-0	-0
Long-Term Deferred Tax Assets	1,687	1,846	1,666	1,612	1,400	1,394
Other Long-Term Assets	3,873	3,996	3,379	3,570	3,790	3,418
Total Assets	141,482	137,497	129,484	124,409	121,213	114,307
Accounts Payable	7,898	5,791	7,256	7,060	6,815	4,746
Accrued Expenses	1,397	1,424	902.13	845.07	864.38	784.18
Short-Term Debt	38,406	20,374	20,706	16,142	11,794	12,720
Current Portion of Long-Term Debt	1,476	21,930	20,793	18,384	12,629	8,590
Current Portion of Leases	88.52	127.34	170.47	76.79	132.21	116.44
Current Income Taxes Payable	891.73	801.32	273.84	169.82	186.45	-
Other Current Liabilities	12,172	9,916	8,999	9,042	9,907	6,962
Total Current Liabilities	62,330	60,363	59,101	51,720	42,327	33,919
Long-Term Debt	840	1,209	3,822	9,843	18,865	24,676
Long-Term Leases	35.27	55.28	115.36	59.01	61.44	133.54
Pension & Post-Retirement Benefits	-	-	-	-	115.17	198.36
Other Long-Term Liabilities	1,376	1,350	877.82	696.83	313.31	580.1
Total Liabilities	64,581	62,977	63,915	62,319	61,682	59,507
Common Stock	7,585	7,585	7,585	7,585	7,585	7,585
Additional Paid-In Capital	14,450	14,450	14,450	14,450	14,450	14,450
Retained Earnings	58,836	53,236	44,875	41,019	37,478	32,890
Comprehensive Income & Other	-3,648	-442.37	-1,037	-759.18	184.15	1.31
Total Common Equity	77,223	74,829	65,874	62,295	59,698	54,927
Minority Interest	-323.13	-308.99	-304.86	-204.62	-166.81	-126.43
Shareholders' Equity	76,900	74,520	65,569	62,090	59,531	54,800
Total Liabilities & Equity	141,482	137,497	129,484	124,409	121,213	114,307
Total Debt	40,846	43,695	45,606	44,505	43,481	46,236
Net Cash (Debt)	-36,473	-39,818	-45,066	-44,158	-41,241	-45,437
Net Cash Per Share	-2407.11	-2624.72	-2968.47	-2910.81	-2718.51	-2995.06
Filing Date Shares Outstanding	15.15	15.17	15.17	15.17	15.17	15.17
Total Common Shares Outstanding	15.15	15.17	15.17	15.17	15.17	15.17
Working Capital	904.27	-942.28	-7,608	-4,612	2,720	2,548
Book Value Per Share	5096.21	4932.54	4342.22	4106.33	3935.14	3620.62
Tangible Book Value	76,664	74,266	65,293	61,709	59,106	54,428
Tangible Book Value Per Share	5059.31	4895.40	4303.95	4067.68	3896.09	3587.73
Land	13,944	13,944	13,944	13,944	13,860	13,722
Buildings	44,709	44,666	44,477	44,264	44,093	43,922
Machinery	35,586	34,812	33,875	32,628	27,545	26,864
Construction In Progress	-	375.5	-	-	-	-